Cargando…
A Novel Deep Neural Network Technique for Drug–Target Interaction
Drug discovery (DD) is a time-consuming and expensive process. Thus, the industry employs strategies such as drug repositioning and drug repurposing, which allows the application of already approved drugs to treat a different disease, as occurred in the first months of 2020, during the COVID-19 pand...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954728/ https://www.ncbi.nlm.nih.gov/pubmed/35336000 http://dx.doi.org/10.3390/pharmaceutics14030625 |
_version_ | 1784676165121736704 |
---|---|
author | de Souza, Jackson G. Fernandes, Marcelo A. C. de Melo Barbosa, Raquel |
author_facet | de Souza, Jackson G. Fernandes, Marcelo A. C. de Melo Barbosa, Raquel |
author_sort | de Souza, Jackson G. |
collection | PubMed |
description | Drug discovery (DD) is a time-consuming and expensive process. Thus, the industry employs strategies such as drug repositioning and drug repurposing, which allows the application of already approved drugs to treat a different disease, as occurred in the first months of 2020, during the COVID-19 pandemic. The prediction of drug–target interactions is an essential part of the DD process because it can accelerate it and reduce the required costs. DTI prediction performed in silico have used approaches based on molecular docking simulations, including similarity-based and network- and graph-based ones. This paper presents MPS2IT-DTI, a DTI prediction model obtained from research conducted in the following steps: the definition of a new method for encoding molecule and protein sequences onto images; the definition of a deep-learning approach based on a convolutional neural network in order to create a new method for DTI prediction. Training results conducted with the Davis and KIBA datasets show that MPS2IT-DTI is viable compared to other state-of-the-art (SOTA) approaches in terms of performance and complexity of the neural network model. With the Davis dataset, we obtained 0.876 for the concordance index and 0.276 for the MSE; with the KIBA dataset, we obtained 0.836 and 0.226 for the concordance index and the MSE, respectively. Moreover, the MPS2IT-DTI model represents molecule and protein sequences as images, instead of treating them as an NLP task, and as such, does not employ an embedding layer, which is present in other models. |
format | Online Article Text |
id | pubmed-8954728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89547282022-03-26 A Novel Deep Neural Network Technique for Drug–Target Interaction de Souza, Jackson G. Fernandes, Marcelo A. C. de Melo Barbosa, Raquel Pharmaceutics Article Drug discovery (DD) is a time-consuming and expensive process. Thus, the industry employs strategies such as drug repositioning and drug repurposing, which allows the application of already approved drugs to treat a different disease, as occurred in the first months of 2020, during the COVID-19 pandemic. The prediction of drug–target interactions is an essential part of the DD process because it can accelerate it and reduce the required costs. DTI prediction performed in silico have used approaches based on molecular docking simulations, including similarity-based and network- and graph-based ones. This paper presents MPS2IT-DTI, a DTI prediction model obtained from research conducted in the following steps: the definition of a new method for encoding molecule and protein sequences onto images; the definition of a deep-learning approach based on a convolutional neural network in order to create a new method for DTI prediction. Training results conducted with the Davis and KIBA datasets show that MPS2IT-DTI is viable compared to other state-of-the-art (SOTA) approaches in terms of performance and complexity of the neural network model. With the Davis dataset, we obtained 0.876 for the concordance index and 0.276 for the MSE; with the KIBA dataset, we obtained 0.836 and 0.226 for the concordance index and the MSE, respectively. Moreover, the MPS2IT-DTI model represents molecule and protein sequences as images, instead of treating them as an NLP task, and as such, does not employ an embedding layer, which is present in other models. MDPI 2022-03-11 /pmc/articles/PMC8954728/ /pubmed/35336000 http://dx.doi.org/10.3390/pharmaceutics14030625 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article de Souza, Jackson G. Fernandes, Marcelo A. C. de Melo Barbosa, Raquel A Novel Deep Neural Network Technique for Drug–Target Interaction |
title | A Novel Deep Neural Network Technique for Drug–Target Interaction |
title_full | A Novel Deep Neural Network Technique for Drug–Target Interaction |
title_fullStr | A Novel Deep Neural Network Technique for Drug–Target Interaction |
title_full_unstemmed | A Novel Deep Neural Network Technique for Drug–Target Interaction |
title_short | A Novel Deep Neural Network Technique for Drug–Target Interaction |
title_sort | novel deep neural network technique for drug–target interaction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954728/ https://www.ncbi.nlm.nih.gov/pubmed/35336000 http://dx.doi.org/10.3390/pharmaceutics14030625 |
work_keys_str_mv | AT desouzajacksong anoveldeepneuralnetworktechniquefordrugtargetinteraction AT fernandesmarceloac anoveldeepneuralnetworktechniquefordrugtargetinteraction AT demelobarbosaraquel anoveldeepneuralnetworktechniquefordrugtargetinteraction AT desouzajacksong noveldeepneuralnetworktechniquefordrugtargetinteraction AT fernandesmarceloac noveldeepneuralnetworktechniquefordrugtargetinteraction AT demelobarbosaraquel noveldeepneuralnetworktechniquefordrugtargetinteraction |